About this Research Topic
Renal cell carcinoma (RCC) stands as the third most prevalent type of urinary system cancer, highlighting an acute requirement for refined diagnostic markers and tailored therapeutic approaches in its advanced stages. Traditional biomarkers such as VEGF, VEGFR-2, and CA9, driven by HIF-1α activities, are now complemented by exosomes. These vesicles have garnered attention for their non-invasive biomarker potential through intercellular communication, carrying proteins, mRNAs, miRNAs, and other pivotal signaling molecules.
This Research Topic aims to explore the expansive potential of exosomes in the diagnosis and treatment of RCC. Aside from their role in advanced and metastatic cases, their involvement in key cancer processes such as PMN formation, angiogenesis, and drug resistance through miRNA and protein exchange could revolutionize RCC management. The integration of nanotechnologies to refine exosome isolation and analysis further underscores this potential.
To gather further insights into this promising field, we welcome articles addressing, but not limited to, the following themes:
o Exosome roles in RCC angiogenesis and metastasis
o Non-invasive diagnostic advancements using tumor-derived exosomes
o Clinical trials validating exosomes as reliable biomarkers
o Nanotechnology applications in exosome research for RCC
o Prospective designs and outcomes in exosome-based therapies
o Development of exosome-mediated tumor vaccines
o Investigation into exosomal mechanisms in drug resistance
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
This Research Topic aims to explore the expansive potential of exosomes in the diagnosis and treatment of RCC. Aside from their role in advanced and metastatic cases, their involvement in key cancer processes such as PMN formation, angiogenesis, and drug resistance through miRNA and protein exchange could revolutionize RCC management. The integration of nanotechnologies to refine exosome isolation and analysis further underscores this potential.
To gather further insights into this promising field, we welcome articles addressing, but not limited to, the following themes:
o Exosome roles in RCC angiogenesis and metastasis
o Non-invasive diagnostic advancements using tumor-derived exosomes
o Clinical trials validating exosomes as reliable biomarkers
o Nanotechnology applications in exosome research for RCC
o Prospective designs and outcomes in exosome-based therapies
o Development of exosome-mediated tumor vaccines
o Investigation into exosomal mechanisms in drug resistance
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Renal Cell Cancer, Exosomes, Tumor Microenvironment, mRNA, miRNA, Biomarker, Drug Resistance
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
